SGP vs JBIO
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SGP · SpyGlass Pharma$30.43 ▼ 1.14%
JBIO · Jade Biosciences$15.31 ▲ 1.66%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SGP +15.3%
- JBIO -0.1%
Head to head
| Metric | SGP | JBIO |
|---|---|---|
| Price | $30.43 | $15.31 |
| Change today | ▼ 1.14% | ▲ 1.66% |
| Market cap | $1.02B | $1.06B |
| Return, 3 months | +15.9% | -28.2% |
| Return, year to date | – | -0.8% |
| Return, 1 year | – | +27.6% |
| P/E (TTM) | – | – |
| P/B | 4.8 | 2.3 |
| P/E percentile vs own 5y | 55th | 11th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -147.1% | -39.2% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -114.4% | -51.4% |
| Analyst target vs. price | +44.6% | +244.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 47 | 51 |
| 30-day volatility | 66.7% | 53.3% |
| Max drawdown, 1 year | -40.8% | -50.1% |
| Trend read | Leaning bearish | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- JBIO is the largest of the group by market value.
- JBIO has been the calmest stock over the last 30 days.